Pharming Ruconest
The Netherlands-based Pharming Group, a specialty pharmaceutical company, have seen encouraging results from it RUCONEST (recombinant human C1 inhibitor) treatment in patients with confirmed COVID-19 infections. The patients were treated under a compassionate use program at the University Hospital Basel, Switzerland. Dr. Michael Osthoff, University Hospital Basel, Switzerland and the treating physician, said: “Although this […]
